Rivenprost_product_DataBase

Bioactivity	Rivenprost is a selective agonist for prostaglandin E receptor EP4 with Ki of 0.7 nM. Rivenprost exhibits hepatoprotective and bone anabolic effects[1][2].
Invitro	Rivenprost (1 nM–1 μM) 通过上调 Runx2 和 Osterix 的表达，刺激成骨细胞分化，从而增加骨形成[1]。Rivenprost (1 nM–1 μM) 通过下调 PPARγ 的 mRNA 水平抑制骨中脂肪细胞分化[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Rivenprost 相关抗体: RT-PCR[1] Cell Line:
In Vivo	Rivenprost (10 μg/kg，皮下注射 5 周) 可增加 Sprague-Dawley 大鼠的骨形成，降低年龄依赖性的脂肪细胞水平[1]。Rivenprost (0.2 mg/kg，腹腔注射，单剂量) 通过炎症细胞因子如 TNF-α 对 Wistar 大鼠中 GalN-/LPS- 诱导的肝损伤具有肝保护作用[2]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:
CAS	256382-08-8
Formula	C24H34O6S
Molar Mass	450.59
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Ninomiya T, et al., Prostaglandin E(2) receptor EP(4)-selective agonist (ONO-4819) increases bone formation by modulating mesenchymal cell differentiation. Eur J Pharmacol. 2011 Jan 10;650(1):396-402. [2]. Kasai K, et al., A novel prostaglandin E receptor subtype agonist, 0N0-4819, attenuates acute experimental liver injury in rats. Hepatol Res. 2001 Nov;21(3):252-260.

PeptideDB

Rivenprost

CAS: 256382-08-8 F: C24H34O6S W: 450.59